secwatch.observer — SEC 8-K summary
======================================

Issuer:     Greenland Mines Ltd (GRML)
CIK:        0001907223
Form:       8-K
Filed at:   2025-07-10T23:59:59+00:00
Accession:  0001213900-25-062859
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA grants Orphan Drug Designation for Klotho's KLTO-202 to treat ALS
---------------------------------------------------------------------

- FDA granted Orphan Drug Designation for KLTO-202 (s-KL-AAV.myo) for ALS.
- Designation provides tax credits for clinical trials, GDUFA fee waiver, and 7-year U.S. market exclusivity.
- Company completed proof-of-concept in two animal ALS models; initiating manufacturing and FDA/EMA meetings.
- KLTO-202 is a gene therapy using a muscle-specific desmin promoter to deliver secreted-Klotho protein.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1907223/000121390025062859/0001213900-25-062859-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1907223/000121390025062859/ea0248604-8k_klotho.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-062859

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer